GlassScriptPhysician profile
Paula H Dunn
NPI 1063864775
$4,459.65
in general payments reported to CMS, 2019-2025
35 companies · $851 in 2025
The $851 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $354 · 2020: $423 · 2021: $506 · 2022: $515 · 2023: $827 · 2024: $982 · 2025: $851.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,660.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $748.90 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $630.97 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $413.38 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $402.95 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $374.43 | 2021-2024 | Vraylar, Ubrelvy, Qulipta |
| Abbott Laboratories | $212.53 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $179.24 | 2019-2024 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.99 | 2021-2025 | Jardiance, Synjardy, Jascayd |
| Lilly USA, LLC | $152.31 | 2020-2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $122.09 | 2023-2025 | |
| Exact Sciences Corporation | $118.46 | 2024-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $112.63 | 2023-2025 | Veozah |
| Amgen INC. | $102.24 | 2019-2023 | Otezla, Repatha |
| Xeris Pharmaceuticals, INC. | $85.06 | 2023-2025 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $68.08 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $67.33 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.34 | 2021-2022 | |
| Ibsa Pharma INC. | $38.08 | 2021-2023 | Tirosint, Licart |
| Biohaven Pharmaceutical Holding Company LTD. | $37.00 | 2022 | |
| Corcept Therapeutics | $36.17 | 2024-2025 | Korlym |
| Boston Scientific Corporation | $33.94 | 2022-2025 | Wavewriter Alpha Prime 16 |
| Esperion Therapeutics, INC. | $32.08 | 2020-2025 | Nexletol |
| Teva Pharmaceuticals USA, INC. | $29.70 | 2022 | |
| Allergan, INC. | $28.97 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $28.09 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $24.32 | 2023 | Rexulti |
| Alkermes, INC. | $22.89 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $22.45 | 2024 | Eliquis |
| Dermira, INC. | $19.66 | 2020 | |
| Dexcom, INC. | $17.56 | 2021 | |
| Amneal Pharmaceuticals LLC | $16.83 | 2024 | Unithroid |
| Seqirus USA INC | $16.77 | 2024 | Fluad, Flucelvax |
| Kowa Pharmaceuticals America, INC. | $15.90 | 2023 | Livalo, Seglentis |
| Philips North America LLC | $15.56 | 2024 | (Ck7) Extended Holter |
| Supernus Pharmaceuticals, INC. | $13.75 | 2023 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paula Dunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.